Biocon gains after its arm inks pact with Amgen to commercialize Denosumab biosimilars in Europe, ROW
Biocon is currently trading at Rs 403.50, up by 3.35 points or 0.84% from its previous closing of Rs 400.15 on the BSE.
The scrip opened at Rs 404.60 and has touched a high and low of Rs 407.40 and Rs 402.40 respectively. So far 97011 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52-week high of Rs 424.95 on 18-Nov-2025 and a 52-week low of Rs 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs 407.40 and Rs 390.25 respectively. The current market cap of the company is Rs 53893.00 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.
Biocon’s subsidiary -- Biocon Biologics has entered into settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world (ROW). The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025. The other terms of the settlement remain confidential.
The European Commission (EC) had approved Vevzuo and Evfraxy in July 2025. Biocon Biologics had secured a market entry date for its Denosumab biosimilars Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) for the United States previously.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
